A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
A phase 3 trial of SHR-A2009, Aumolertinib in non-small-cell lung cancer and small-cell lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
Overview
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC is a phase 3 interventional study registered as NCT07183189 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 576 participants planned, started 2025-10-30 and due to reach its primary completion in 2032-11. Interventions recorded: SHR-A2009 ; Aumolertinib, Aumolertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
Shares SHR-A2009, Jiangsu Hengrui Pharmaceuticals, Non-small-cell lung cancer.
- TrialAlmonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations
Shares Aumolertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialAumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mut
Shares Aumolertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer
Shares Aumolertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Shares SHR-A2009, Aumolertinib, Jiangsu Hengrui Pharmaceuticals.
- TrialA Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC
Shares Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialPhase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Adva
Shares Jiangsu Hengrui Pharmaceuticals, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer
Shares SHR-A2009, Jiangsu Hengrui Pharmaceuticals.